Clinical Trials
3 trialsNCT03255070 2024-02-01
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
Phase 1 Completed
NCT05041972 2022-09-13
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
Phase 2 Withdrawn
NCT02512237 2020-06-05
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Zhejiang Medicine Co., Ltd.
Phase 1 Terminated